We report a rare case of chondrosarcoma metastatic to the choroid. A 64-year-old male with a history of chondrosarcoma metastatic to the lungs and to the spine presented with blurred vision. A choroidal tumor was found. Fine-needle biopsy confirmed the histologic identity of the tumor as chondrosarcoma. Metastatic spread of chondrosarcoma to the eye is extremely rare. When present, lesions may grow rapidly, and systemic prognosis is poor. Co-management with medical oncology is of utmost importance. This is the third case of chondrosarcoma metastatic to the choroid in the literature and the first with bilateral involvement.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615329 | PMC |
| http://dx.doi.org/10.1159/000494979 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chondrosarcoma proximal tibia secondary to chondromyxoid fibroma: A rare case report.
Int J Surg Case Rep
January 2025
Department of Orthopaedics, All India Institute of Medical Sciences (AIIMS), Marudhar Industrial Area, 2nd phase, M.I.A. 1st phase, Basni, Jodhpur, Rajasthan 342005, India.
Introduction: Benign cartilage tumours with malignant transformation are reported very few. Aiming to report a secondary chondrosarcoma in proximal tibia after chondromyxoid fibroma: a rare entity with limited experience of management.
Case Presentation: we present a challenging case of secondary chondrosarcoma of proximal tibia in surgically managed chondromyxoid fibroma.
Aggressive Subtypes of Laryngeal Chondrosarcoma and their Clinical Behavior: A Systematic Review.
Oncol Ther
January 2025
Coordinator of the International Head and Neck Scientific Group, Padua, Italy.
Introduction: Laryngeal chondrosarcoma (CS) is a rare indolent malignant tumor. High-grade (G3), dedifferentiated (DD), and myxoid (MY) CSs are considered more aggressive subtypes due to their metastatic potential and relatively poor outcomes. The aim of this systematic review is to evaluate treatment modalities and survival outcomes in patients affected by these rarer CS subtypes.
View Article and Find Full Text PDFHigh-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation.
Int J Mol Sci
December 2024
Department of Medicine, Division of Medical Oncology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
The term chondrosarcoma refers to a rare and heterogeneous group of malignant cartilaginous tumors that are typically resistant to chemotherapy and radiotherapy. Metastatic chondrosarcoma has a poor prognosis, and effective systemic therapies are lacking. Isocitrate dehydrogenase (IDH) mutations represent a potential therapeutic target, but IDH inhibitors alone have shown limited clinical efficacy to date.
View Article and Find Full Text PDFRare malignant primary spinal chondrosarcoma: A case report.
Radiol Case Rep
February 2025
Department of Pathology Anatomy, Faculty of Medicine PADJADJARAN University. Dr. Hasan Sadikin Hospital, Bandung, West Java, Indonesia.
Article Synopsis
- Chondrosarcomas are malignant tumors that produce cartilage and are divided into primary and secondary types; primary chondrosarcomas are the third most common primary malignant bone tumors, accounting for 20%-27% of cases.
- A case study involving a 36-year-old man revealed a rare primary spinal chondrosarcoma with symptoms of back swelling and pain over 3 years, confirmed through imaging that showed a lytic sclerotic lesion and extensive infiltration.
- Diagnosis relies on imaging techniques like X-rays, CT, and MRI, and treatment typically involves en bloc resection and possibly high-dose radiotherapy to improve outcomes and monitor for recurrence.
Advancing Systemic Therapy in Chondrosarcoma: New Horizons.
Oncol Ther
December 2024
Sarcoma Unit, Royal Marsden and Institute of Cancer Research, London, UK.
Article Synopsis
- The treatment of advanced chondrosarcoma, which often doesn't respond well to standard chemotherapy, is currently being explored through targeted therapies aimed at specific genetic mutations and signaling pathways.
- New strategies include utilizing IDH inhibitors for tumors with IDH mutations, hedgehog pathway inhibitors, and various forms of immunotherapy, all facing challenges but showing potential for effectiveness.
- There's a strong emphasis on using personalized, multi-omics approaches to create combination therapies that can better address the heterogeneous nature of chondrosarcoma and possibly improve treatment outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!